HomeBUSINESS
BUSINESS

JCR Files Fabrazyme Biosimilar for Japan Approval
(Oct.3.2017)

JCR Pharmaceuticals said on September 29 that it filed on the same day for Japanese regulatory approval of JR-051, a biosimilar version of Genzyme Japan’s Fabry’s disease treatment Fabrazyme (agalsidase beta) ...
(LOG IN FOR FULL STORY)

News Calendar